Jose Mario F De Oliveira
Universidade Federal Fluminense, Brazil
Posters & Accepted Abstracts: J Diabetes Metab
Albeit diagnosed and defined as a �??primary sugar disease of the adult�?�; i.e, also as namely a disease of the carbohydrate metabolism by mostly authors; so called type 2 diabetes mellitus should be better defined as a �??No Man´s Land�?� state of disease in adults, at most diagnosed by a fasting glycaemia equal or higher than 126 mg/dL. And why this reality? Because in a global epidemic, which is badly out of control, among other reasons. there is not much time to loose. So let´s get into some facts! Despite all controversies surrounding the etiology, pathogenesis, and therapeutic roles for hyperglycaemia in type 2 diabetes mellitus, newer anti-hyperglycaemic drugs are still getting onto the market at a high speed, due to the overconfidence in HbA1c as a surrogate outcome for microvascular complications; albeit. All large recent randomised clinical trials and meta-analysis have shown that trying to achieve glycaemic levels close to the normal range did not reduce the most clinically important microvascular or macrovascular hard endpoints as end-stage renal disease, vision loss, stroke, cardiovascular and total mortality, with the added harm of substantial increase in the number of hypoglycaemic episodes, and even death rates. If glucose or HbA1c were good surrogate disease markers why the increased mortality in the ACCORD trial and the recent rosiglitazone saga, among other anti-hyperglycaemic drugs? The above, among other core issues, will be covered in our talk.
Email: jmariofranco@gmail.com
